Gentium S.p.A.
http://www.gentium.it/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gentium S.p.A.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Zydus Cadila Testing Three-Dose COVID-19 Vaccine
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Stryker Exercises New Innovation Muscles During COVID-19
Many changes have come about for the orthopedic innovator Stryker as a result of the pandemic, says group CEO Kevin Lobo. The most important relates to methods of engagement with customers.
APACMed 2020: Stryker Is Exercising New Innovation Muscles During COVID-19
Many changes have come about for the orthopedic innovator Stryker as a result of the pandemic, says group CEO Kevin Lobo. The most important relates to methods of engagement with customers.